Brainstorm Cell Therapeutics Inc.
BCLI- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001137883
No open-market purchases or sales by Brainstorm Cell Therapeutics Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding Brainstorm Cell Therapeutics Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Of which not filed for Q4 2024 | Q4 2024 | Change |
|---|---|---|---|---|
| Holders | 38 | 1 | 34 | −3 |
| SharesConverted for a 1-for-15 split | 732.1K | 6.34K | 404.0K | −321.7K (−44.3%) |
| Value | $2.52M | $21.9K | $560.3K | −$1.94M (−77.6%) |
1 institution that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (14)
Institutions that held Brainstorm Cell Therapeutics Inc. at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| HRT Financial LP | 20,022 | $45.0K | 0.00% |
| Ikarian Capital, LLC | 6,016 | $13.7K | 0.00% |
| Citigroup Inc | 1,971 | $4.47K | 0.00% |
| SBI Securities Co., Ltd. | 167 | $379 | 0.00% |
| Transce3nd, LLC | 148 | $336 | 0.00% |
| EverSource Wealth Advisors, LLC | 141 | $320 | 0.00% |
| VSM Wealth Advisory, LLC | 120 | $272 | 0.00% |
| FMR LLC | 111 | $252 | 0.00% |
| Cranbrook Wealth Management, LLC | 66 | $150 | 0.00% |
| BNP Paribas Arbitrage, SA | 24 | $54 | 0.00% |
| Centricity Wealth Management, LLC | 20 | $45 | 0.00% |
| CBIZ Investment Advisory Services, LLC | 13 | $30 | 0.00% |
| CoreCap Advisors, LLC | 8 | $18 | 0.00% |
| Caldwell Sutter Capital, Inc. | 157,009 | $0 | 0.00% |
Sold out (17)
Institutions that held Brainstorm Cell Therapeutics Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Armistice Capital, LLC | 6,897,653 | $1.59M |
| Abner Herrman & Brock LLC | 145,500 | $34.0K |
| State Street Corp | 117,260 | $27.0K |
| Northern Trust Corp | 112,358 | $25.9K |
| Jmac Enterprises LLC | 65,430 | $15.1K |
| XTX Topco Ltd | 53,088 | $12.2K |
| Group One Trading, L.P. | 46,754 | $10.8K |
| Tru Independence Asset Management 2, LLC | 44,000 | $10.1K |
| Tower Research Capital LLC (TRC) | 23,356 | $5.37K |
| Janney Montgomery Scott LLC | 20,500 | $5.00K |
| Creative Planning | 13,846 | $3.19K |
| Saxony Capital Management, LLC | 12,950 | $2.98K |
| Bank of New York Mellon Corp | 11,994 | $2.76K |
| Jump Financial, LLC | 10,995 | $2.53K |
| Bangor Savings Bank | 4,000 | $921 |
| Reuter James Wealth Management, LLC | 1,034 | $238 |
| Simplex Trading, LLC | 1,150 | $0 |
Not filed for Q4 2024 yet (1)
Institutions that held Brainstorm Cell Therapeutics Inc. at the end of Q3 2024 and haven't filed a 13F for Q4 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Raymond James & Associates | 95,153 | $21.9K |